Nerve-on-Chips

Información del proyecto

NOC

Identificador del acuerdo de subvención: 743909

DOI

10.3030/743909

Proyecto cerrado

Fecha de la firma de la CE 7 Diciembre 2016

Fecha de inicio 1 Diciembre 2016

Fecha de finalización 31 Mayo 2017

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

MICROBRAIN BIOTECH
France

Periodic Reporting for period 1 - NOC (Nerve-on-Chips)

Período documentado: 2016-12-01 hasta 2017-05-31

Resumen del contexto y de los objetivos generales del proyecto

Neurodegenerative diseases (hereafter “ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).

MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (hereafter “NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

A legal feasibility study ensured freedom to operate.

A Business and market analysis allowed us to get in-depth knowledge of the challenges linked to drug discovery, the Organ-on-Chip (OOC) market and the OOC ecosystem, stakeholders, and competitors.

Microfabrication-based methods have been validated to guide network self-assembly, accomplishing control over in vitro circuit size and connectivity. The general goal was to define the best technological opportunities in terms of microfabrication, biological validation, and screening.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models:

- Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness)
- Reduce animal testing
- Predicting human-relevant drug responses
- Compatibility with readouts used in biology
- Reconstitution of complex organ-level physiological functions- Real-time visualization

NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study allowed us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.

logo-mbbt.png